The BOLERO‐2 trial established everolimus plus exemestane as an effective strategy for endocrine‐resistant, hormone receptor–positive/HER2(–) advanced breast cancer, leading to regulatory approval [161]. This evidence concerns the gene NR4A1 and breast carcinoma.